Press release

Siemens Healthineers AG successfully debuts on the Frankfurt Stock Exchange

Published on March 17, 2018
  • First official price of € 29.10 above final placement price
  • Successful listing allows Siemens Healthineers to help shape the future of healthcare

Siemens Healthineers AG (“Siemens Healthineers”), a leading supplier of innovative solutions to healthcare providers worldwide, celebrated its successful market debut today with its shares trading for the first time on the Frankfurt Stock Exchange. At
€ 29.10 per Siemens Healthineers share, the first stock exchange quotation was well above the final placement price of € 28.00. In total, 150,000,000 existing ordinary registered shares (including over-allotments) were placed at the IPO, representing a free float of 15 percent.

“We are proud and excited to have reached this important milestone. The successful listing puts us in an even better position than before: As an independent global healthcare leader at the forefront of innovation and with a clear strategy to capture the opportunity our transforming market provides, we have the strength to help shape the future of healthcare”, said Bernd Montag, CEO of Siemens Healthineers. “The listing gives us the entrepreneurial flexibility necessary to lay the foundation for further growth, and with Siemens AG we retain a committed, long-term majority shareholder on board that fully supports our strategy and growth plans.”

Siemens AG holds a 85 percent stake in Siemens Healthineers following the IPO, assuming full exercise of the Greenshoe Option.

Michael Sen, Chairman of the Siemens Healthineers Supervisory Board and member of the Siemens AG Managing Board as well as the Siemens Healthineers Executive Management Team – CEO Bernd Montag, CFO Jochen Schmitz and Managing Board Member Michael Reitermann – rang the bell on the trading floor of the Frankfurt Stock Exchange to symbolically open the trading of shares.

With its Strategy 2025, Siemens Healthineers has laid out its path for the future. The company is well prepared to take advantage of the paradigm shift and structural growth opportunities in healthcare. In order to share its success with investors, Siemens Healthineers targets a dividend payout ratio of 50 to 60 percent of the company’s net income.

Siemens Healthineers shares, trading under the ticker symbol SHL, are listed in the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange. The International Securities Identification Number (ISIN) is DE000SHL1006, and the German Securities Code (WKN) is SHL 100.

Retail investors that placed orders with syndicate banks were allocated approximately 7.6% of the total placement volume of, in aggregate, 150,000,000 shares (including 19,565,217 shares in connection with over-allotments). As the offer was oversubscribed, not all purchase orders from retail investors could be considered in full. All orders placed by retail investors with syndicate banks were allocated according to the following allocation key: Each order was allocated 100 shares. Orders for the next 1,900 shares were allocated at 30%. The principles for the allocation of shares to retail investors issued by the ministry of finance’s stock exchange expert commission were followed and the allocation to retail investors in connection with the offering followed the same criteria for all syndicate banks and their affiliated institutions.

Link to the press pictures

Siemens Healthineers

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2017, which ended on September 30, 2017, Siemens Healthineers generated revenue of €13.8 billion and profit of €2.5 billion and has about 48,000 employees worldwide.